Navigation Links
ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference
Date:1/28/2009

Kristin Lucas, ClearTrial Senior Director of Clinical Services, will lead a panel of top pharmaceutical financial experts in discussing "Methodologies for Managing Cash Flow and Accruals" at the CBI Forecasting & Budgeting conference. The panel will demonstrate practical ways to gain greater control over clinical trial budgets and improve management of clinical trial cash flow and accruals.

Chicago, IL (PRWEB) January 28, 2009 -- ClearTrial (www.cleartrial.com), a leading provider of clinical trial software for clinical trial operations planning, budgeting, and outsourcing, announced today that Kristin Lucas, ClearTrial Senior Director of Clinical Services, will lead a panel of top pharmaceutical financial experts in discussing "Methodologies for Managing Cash Flow and Accruals" at the CBI Forecasting & Budgeting conference. Held at the Crowne Plaza Hotel in Philadelphia, February 3-4, 2009, the conference will bring together senior biopharma executives in clinical operations and finance to share best practices.

With the complexity of clinical trials increasing, managing cash flow and accruals presents significant challenges to clinical operations and financial professionals at biopharma companies. The panel of experts will present proven guidelines for managing accruals in order to effectively manage clinical cash flow, including:

  • Obtaining accurate assessments of accruals based on actual work performed
  • Tracking contract performance and timelines
  • Accurately forecasting and managing one-time start-up fees
  • Effectively managing clinical cash flow

Lucas brings more than 15 years of experience in the pharmaceutical and biotech industry to the conference, with extensive experience in clinical trial budgeting and contract management. Before joining ClearTrial, she led the Financial Administration division for the Clinical Business Management department at ICOS Corporation (an Eli Lilly company), where she worked on the blockbuster drug Cialis®. At ICOS, Lucas was responsible for establishing best practices in the outsourcing, management, drafting and negotiation of site and vendor agreements, as well as the development of a clinical budgeting/modeling application for lifecycle planning, budgeting and in-licensing opportunity assessment. Prior to ICOS, Lucas spent seven years with Genentech, where she was responsible for the negotiation, positioning, and pricing strategy for managed care contracts.

About ClearTrial®
ClearTrial® is a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing. ClearTrial's award-winning software helps pharmaceutical, biotechnology, medical device companies, and CROs expedite the clinical development process without sacrificing quality of results. The company's software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information please visit http://www.cleartrial.com.

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.

###

Read the full story at http://www.prweb.com/releases/2009/01/prweb1923824.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
2. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
3. Metastorm Selected as a Finalist in ACG Deal of the Year Awards
4. Netsmart Technologies Selected by City and County of San Francisco to Provide Integrated Behavioral Healthcare Software System
5. NEXCORE Technology Selected to Manufacture New Endoscopic Cryotherapy Device
6. Fujitsu PalmSecure and HT Systems PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft
7. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
8. Animetrics Inc. Selected to Provide 3D Face Viewer Technology for United States Army Biometric Automated Toolset (BAT)
9. Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products
10. Sparta Systems Selected by Genzyme to Optimize Quality Assurance Processes with TrackWise
11. Cardium Selected for Inclusion in Russell Microcap Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 2017 , ... Total Orthopedics and Sports Medicine ( http://www.totalorthosportsmed.com ... operation took place on Wednesday, January 11, 2017 at Long Island Jewish, Valley ... discectomy and fusion on a 42 year old female who was in a ...
(Date:1/18/2017)... FL (PRWEB) , ... January 18, 2017 , ... ... weakness and paralysis, today announced that it has submitted a 510(k) to the ... bikes that utilize MYOLYN’s patent-pending functional electrical stimulation (FES) technology. , The ...
(Date:1/18/2017)... ... January 18, 2017 , ... BidMed, LLC, announced it will ... genetic testing lab equipment from two different leading institutes. This highly specialized laboratory equipment ... the United States. This 1-day online auction will take place on BidMed’s website ...
(Date:1/18/2017)... 18, 2017 Shareholder rights law firm Johnson ... the board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... with the proposed sale of the Company to Eli ... develops small molecules for the acute treatment of migraines. ... had signed a definitive merger agreement with Eli Lilly. ...
Breaking Biology Technology:
(Date:1/3/2017)... LAS VEGAS , Jan. 3, 2017 ... announced the introduction of Onitor Track, an innovative biometric ... and men, showcasing this month at the 2017 Consumer ... . In the U.S., the World ... affect more than two-thirds of adults who are overweight ...
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, Inc. ... genomics technology company, announced today that on December 13, ... Department of The Nasdaq Stock Market LLC which acknowledged ... price of WaferGen,s common stock had been at $1.00 ... has regained compliance with Listing Rule 5550(a)(2) of the ...
Breaking Biology News(10 mins):